Investor Presentation
Investment Summary
1 Clinically validated, FDA Clearance technology offering superior
outcomes at lower costs compared with incumbent technologies
2 Significant global market with attractive growth drivers in core
geographic regions, Australian TGA approval and FDA 510(k).
clearance received
3 Capital light sales model underpinned by plug-and-play SaaS delivery
leveraging existing X-ray infrastructure, delivering 90%+ gross margin
4 XV Technology platform allows for rapid and efficient deployment of
product to healthcare providers
5 Established relationships with some of the world's most recognized
and acclaimed medical institutions
6 Significant barriers to entry, including first mover advantage, strong IP
portfolio and a strong product pipeline
7 Significant operating leverage with the ability to scale rapidly
8 Highly experienced Board of Directors and senior management team
Pg 34 | Investor presentationView entire presentation